Chief Executive Officer
Aurelia Bioscience, United Kingdom
Gary brings together innovative technology from R&D partners with client projects to create synergies and novel readouts, improving assay quality and reducing client project SAR cycle times. At Aurelia Bioscience, he leverages over 30 years of pre-clinical drug discovery experience and a number of scientific papers in leading journals to aid the discovery of new chemical entities.